| __timestamp | Iovance Biotherapeutics, Inc. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 9335772 | 570979 |
| Thursday, January 1, 2015 | 999000 | 2185000 |
| Friday, January 1, 2016 | 978000 | 4554000 |
| Sunday, January 1, 2017 | 952000 | 3605000 |
| Monday, January 1, 2018 | 956000 | 5527000 |
| Tuesday, January 1, 2019 | 8122999 | 5234000 |
| Wednesday, January 1, 2020 | 8712000 | 6126000 |
| Friday, January 1, 2021 | 13980000 | 6784000 |
| Saturday, January 1, 2022 | 21135000 | 7592000 |
| Sunday, January 1, 2023 | 10755000 | 11450000 |
Data in motion
In the competitive world of biotechnology, cost efficiency can be a decisive factor for success. This analysis compares the cost of revenue efficiency between Iovance Biotherapeutics, Inc. and Travere Therapeutics, Inc. from 2014 to 2023. Over this period, Iovance Biotherapeutics demonstrated a significant increase in cost efficiency, with a peak in 2022 where their cost of revenue was approximately 90% higher than in 2014. Meanwhile, Travere Therapeutics showed a steady increase, culminating in a 100% rise by 2023 compared to their 2014 figures. Notably, Iovance's cost of revenue in 2022 was nearly double that of Travere's, highlighting their aggressive growth strategy. This decade-long journey underscores the dynamic nature of the biotech industry, where strategic financial management is crucial for sustaining growth and innovation.
Cost Insights: Breaking Down Eli Lilly and Company and Travere Therapeutics, Inc.'s Expenses
Cost of Revenue: Key Insights for AstraZeneca PLC and Travere Therapeutics, Inc.
Sanofi vs Iovance Biotherapeutics, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Incyte Corporation vs Iovance Biotherapeutics, Inc.
Cost Insights: Breaking Down Corcept Therapeutics Incorporated and Travere Therapeutics, Inc.'s Expenses
Cost of Revenue Trends: Cytokinetics, Incorporated vs Iovance Biotherapeutics, Inc.
Cost of Revenue: Key Insights for PTC Therapeutics, Inc. and Travere Therapeutics, Inc.
Analyzing Cost of Revenue: Perrigo Company plc and Iovance Biotherapeutics, Inc.
Supernus Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Geron Corporation vs Iovance Biotherapeutics, Inc.
R&D Insights: How Iovance Biotherapeutics, Inc. and Travere Therapeutics, Inc. Allocate Funds
Cost of Revenue Comparison: Iovance Biotherapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.